Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-136598
Filing Date
2024-12-16
Accepted
2024-12-16 16:00:03
Documents
5
Period of Report
2025-01-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A kpti-_2025_spec_meeting-.htm DEF 14A 405156
2 GRAPHIC img220833156_0.jpg GRAPHIC 33329
3 GRAPHIC img220833156_1.jpg GRAPHIC 8774
4 GRAPHIC img220833156_2.jpg GRAPHIC 476307
5 GRAPHIC img220833156_3.jpg GRAPHIC 411979
  Complete submission text file 0000950170-24-136598.txt   1686660
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36167 | Film No.: 241551726
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)